A study of luspatercept versus standard-of-care in the first-line treatment setting for myelodysplastic syndromes (MDS) patients.
Phase of Trial: Phase III
Latest Information Update: 02 May 2017
At a glance
- Drugs Luspatercept (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms COMMANDS
- 02 May 2017 New trial record
- 27 Apr 2017 According to an Acceleron media release, the company expects to initiate this study in early 2018.